embecta opens new global headquarters in Parsippany, N.J.
25 Janvier 2023 - 1:00PM
Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest
pure-play diabetes care companies in the world following its April
1, 2022, spinoff from Becton, Dickinson and Company (“BD”), today
held a grand opening ceremony at its new global headquarters office
at 300 Kimball Drive, Suite 300, in Parsippany, N.J. The site will
be home to members of the leadership team, global support functions
and the North America commercial organization. embecta has
approximately 2,000 employees worldwide.
“With a number of our employees currently making their homes in
New Jersey, the ability to tap into one of the nation’s most
significant concentrations of highly-educated, experienced medical
technology talent, and easy access to international airports and
interstate highways, we see Parsippany as the ideal location to
establish our worldwide headquarters,” said Devdatt (Dev) Kurdikar,
president and chief executive officer, embecta. “We are a new
company, but our roots in New Jersey go back nearly 100 years when,
as part of BD, we developed the first dedicated insulin syringe in
1924. We’re looking forward to advancing that legacy as we continue
to develop and provide solutions that make life better for people
living with diabetes.”
The 55,600-square-foot office suite is designed
to give employees the tools and flexibility they need to
collaborate both in-person and on a global scale as they work with
geographically dispersed teams to meet the needs of customers in
over 100 countries. In addition to ample open workspace, the suite
features numerous spaces for collaboration with the latest video
conferencing technology, huddle rooms, and reservable private
spaces, as well as a showroom for product demonstrations and
on-site customer meetings. CBRE, the world’s largest commercial
real estate services and investment firm, has been embecta’s
partner in choosing, designing and building out the office.
“We’re pleased that embecta has chosen to make a
long-term commitment to New Jersey, adding to the roster of life
sciences and medical technology companies that make the core of the
Garden State’s innovation economy,” said Governor Phil Murphy.
“Diabetes is one of the world’s most pressing health care issues,
with an enormous cost burden and a societal impact that extends to
friends, loved ones and caregivers. embecta’s vision of a life
unlimited by diabetes is closely aligned with our own efforts to
invest in, and expand, the state’s public health
infrastructure.”
About embectaembecta is one of the largest
pure-play diabetes care companies in the world, leveraging its
nearly 100-year legacy in insulin delivery to empower people with
diabetes to live their best life through innovative solutions,
partnerships and the passion of approximately 2,000 employees
around the globe. For more information, visit embecta.com, the
content of which is not a part of this press release.
CONTACTS
Investors:Pravesh KhandelwalVP, Head of
Investor Relations551-264-6547Contact IR
Media:Christian GlazarSr. Director, Corporate
Communications 908-821-6922 Contact Media Relations
Embecta (NASDAQ:EMBCV)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Embecta (NASDAQ:EMBCV)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025